N/A Completed N=20 Randomized Double-blind Treatment

Repetitive Transcranial Magnetic Stimulation (rTMS) in Fibromyalgia

Fibromyalgia

Source: ClinicalTrials.gov NCT03909009 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2020

Primary outcomePrimary: Visual Analog Scale-Pain — 5.30; 6.80 units on a scale

Summary

This study aims to evaluate the effectiveness of 10 Hz neuronavigated repetitive transcranial magnetic stimulation (rTMS) to the left dorsolateral prefrontal cortex (DLPFC) on pain, stiffness, fatigue, depression/anxiety, quality of life and cognitive functions in fibromyalgia syndrome (FMS).

Outcome Measures

Outcome	Result	p-value
PRIMARY Visual Analog Scale-Pain	5.70; 6.70	—
SECONDARY Visual Analog Scale-Pain	5.70; 6.70	—
SECONDARY Fibromyalgia Impact Questionnaire	48.35; 54.39	—

Eligibility Criteria

Inclusion Criteria

Adults (age between 18-65 years)
Diagnosis of fibromyalgia syndrome according to 2016 Fibromyalgia diagnostic criteria
The mean pain intensity is VAS ≥ 4/10
Stable treatment for at least last 3 months
Patients accepting participation by signing an informed consent form

Exclusion Criteria

To have a clinical condition to be contraindicated for TMS (metallic implant, cardiac pace, pregnancy, lactation, epilepsy, head trauma, history of cranial operation...)
The presence of malignancy
Systemic rheumatic diseases
Major orthopedic / neurological problems that limit daily life activities
Alcohol or drug addiction
Major depression / personality disorder history
Have received TMS treatment before
Pregnancy or breastfeeding

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03909009). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.